VentiMate
A wearable device to transform the lives of individuals with asthma or exercise induced bronchoconstriction (EIB)
Breathe easier; live freer with VentiMate
Asthma is one of the most prevalent chronic disorders worldwide
affecting approximately 336 million people globally, and 25 million people in the United States.
EIB is estimated to occur in 90% of patients with asthma and is considered as a trigger of the disease. EIB is common in athletes affecting up to 50%.
Our Vision
To empower millions affected by asthma and EIB with a wearable, non-invasive device that delivers real-time relief. Our device works in a closed-loop fashion, detecting the onset of bronchoconstriction and provided relief. This extends the window for required inhaled medication interventions.
We envision a world where respiratory challenges no longer limit daily life, exercise, or potential. A world where innovative technology enables people to take control of their breathing with confidence and ease.
Our Story
VentiMate is currently under development at the University of Otago, New Zealand.
(PCT filed; priority date 07/11/2023)
We are looking for partners/investors to join our mission. Join us to help patients with asthma enjoy greater freedom, have reduced hospital visits, and enhanced quality of life.